Citation Tools
PDFClinical/translational cancer immunotherapy
Original research
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial